Am I reading between the lines too much? I'm a bit intrigued by the wording, "We plan to build on this sucess in 2013 by generating proof -of- concept data for Z-160 in multiple indicators and continuing the clinical development of Z-944." I interpret that as a strong indicator that they have already determined the Z-169 has passed muster for one or more applications and they are looking at expanded applications. Additionally leaves no question as to Z-944 proceeding as expected.
Jim Long and calm
facts jim facts. z944 was to start phase 2 in Q 1 2013. that is what is expected from shareholders so unless it starts in march the clock is ticking. by the co's wording an experimental study in 2013 and further clinical developement!
You are forgetting to mention one other importtant line in their earnings report: "Nominate a sodium channel lead for further preclinical development in 2013". That means we have another possible drug candidate to look forward to this year. Could Z212 be entering the spotlight?